Usana Health Sciences (USNA) Cost of Revenue (2016 - 2026)
Usana Health Sciences has reported Cost of Revenue over the past 17 years, most recently at $59.4 million for Q2 2026.
- Quarterly Cost of Revenue rose 13.33% to $59.4 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $207.8 million through Apr 2026, up 21.84% year-over-year, with the annual reading at $200.9 million for FY2026, 24.59% up from the prior year.
- Cost of Revenue was $59.4 million for Q2 2026 at Usana Health Sciences, up from $49.4 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $67.8 million in Q1 2022 and troughed at $38.6 million in Q4 2024.
- The 5-year median for Cost of Revenue is $47.5 million (2022), against an average of $47.8 million.
- Year-over-year, Cost of Revenue plummeted 31.53% in 2022 and then grew 28.16% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $46.4 million in 2022, then dropped by 8.85% to $42.3 million in 2023, then fell by 8.9% to $38.6 million in 2024, then increased by 26.62% to $48.8 million in 2025, then rose by 21.76% to $59.4 million in 2026.
- Per Business Quant, the three most recent readings for USNA's Cost of Revenue are $59.4 million (Q2 2026), $49.4 million (Q1 2026), and $48.8 million (Q3 2025).